Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection

BackgroundWhile malignant pleural effusion (MPE) is a common and significant cause of morbidity in patients with cancer, current treatment options are limited. Human heparanase, involved in angiogenesis and metastasis, cleaves heparan sulfate (HS) side chains on the cell surface.AimsTo explore the coagulation milieu in MPE and infectious pleural effusion (IPE) focusing on the involvement of heparanase.MethodsSamples of 30 patients with MPE and 44 patients with IPE were evaluated in comparison to those of 33 patients with transudate pleural effusions, using heparanase ELISA, heparanase procoagulant activity assay, thrombin and factor Xa chromogenic assays and thromboelastography. A cell proliferation assay was performed. EMT-6 breast cancer cells were injected to the pleural cavity of mice. A peptide inhibiting heparanase activity was administered subcutaneously.ResultsLevels of heparanase, factor Xa and thrombin were significantly higher in exudate than transudate. Thromboelastography detected almost no thrombus formation in the whole blood, mainly on MPE addition. This effect was completely reversed by bacterial heparinase. Direct measurement revealed high levels of HS chains in pleural effusions. Higher proliferation was observed in tumour cell lines incubated with exudate than with transudate and it was reduced when bacterial heparinase was added. The tumour size in the pleural cavity of mice treated with the heparanase inhibitor were significantly smaller compared with control (p=0.005).ConclusionsHS chains released by heparanase form an anticoagulant milieu in MPE, preventing local thrombosis and enabling tumour cell proliferation. Inhibition of heparanase might provide a therapeutic option for patients with recurrent MPE.

Download Full-text

Administration of the adriamycin-containing poly (L-lactic acid) microspheres into the pleural cavity of patients with malignant pleural effusion.

Drug Delivery System ◽

10.2745/dds.5.23 ◽

1990 ◽

Vol 5 (1) ◽

pp. 23-27 ◽

Cited By ~ 3

Author(s):

Osamu Ihe ◽

Shigeki Hitomi ◽

Yasuhiko Shimizu ◽

Ryoichi Wada ◽

Satoshi Watanabe ◽

...

Keyword(s):

Lactic Acid ◽

Pleural Effusion ◽

Malignant Pleural Effusion ◽

Pleural Cavity

Download Full-text

THERAPIES OF RESISTANT EXUDATIVE PLEURITIS

Ulyanovsk Medico-biological Journal ◽

10.34014/2227-1848-2020-1-22-30 ◽

2020 ◽

pp. 22-30

Author(s):

A.L. Charyshkin ◽

E.A. Kuzmina ◽

B.I. Khusnutdinov ◽

E.A. Toneev ◽

O.V. Midlenko ◽

...

Keyword(s):

Breast Cancer ◽

Lung Cancer ◽

Ovarian Cancer ◽

Pleural Effusion ◽

Malignant Pleural Effusion ◽

Pleural Cavity ◽

Pleural Empyema ◽

Malignant Neoplasms ◽

Risk Of Infection ◽

Minimally Invasive Methods

In Russia, annually more than 100,000 people are diagnosed with tumor pleuritis. Resistant cancerous pleuritis is often caused by lung cancer (35 %), breast cancer (23 %), ovarian cancer and lymphomas (10 %). Pleuritis in malignant neoplasms often indicates the spread of the process through pleura. At the same time, systemic therapy does not always help patients. Radical treatment for malignant pleural effusion is gradually being replaced by new minimally invasive methods. Prolonged drainage of the pleural cavity in exudative pleuritis increases the risk of infection, which contributes to the development of pleural empyema. In order to eliminate the exudate, talc, tetracycline, and Betadine solutions are introduced into the pleural cavity through the drainage, the efficacy being 60 to 90 %. Thus, a new method for drug administration into the pleural cavity, which helps to eliminate resistant exudative pleuritis, remains relevant. Keywords: resistant exudative pleuriris, malignant neoplasms, pleurodesis. Проведен обзор отечественной и зарубежной литературы, посвященный местному лечению резистентного злокачественного плеврита. С каждым годом частота онкологических заболеваний и опухолевых плевритов только повышается. В России ежегодно опухолевые плевриты диагностируют более чем у 100 000 чел. Резистентный злокачественный плеврит в 35 % случаев обусловлен раком легкого, в 23 % – раком молочной железы, в 10 % – раком яичников и лимфомами. Плеврит при злокачественных новообразованиях часто свидетельствует о распространении процесса по плевре. При этом использование системных методов лечения не всегда облегчает состояние пациента. Радикальные методы лечения злокачественного плеврального выпота постепенно заменяются новыми минимально инвазивными методами. Продолжительное дренирование плевральной полости при экссудативном плеврите увеличивает риск ее инфицирования, что способствует развитию эмпиемы плевры. С целью ликвидации экссудата через установленный дренаж в плевральную полость вводят растворы талька, тетрациклина, бетадина с эффективностью от 60 до 90 %. Недостатком данного способа лечения является выраженный болевой синдром, повышение температуры тела, риск легочных осложнений, длительность лечения. Таким образом, создание способа введения лекарственных препаратов в плевральную полость для ликвидации резистентного экссудативного плеврита остается актуальным. Ключевые слова: резистентный экссудативный плеврит, злокачественные новообразования, плевродез.

Download Full-text

KARAKTERISTIK PASIEN EFUSI PLEURA DI KOTA JAMBI

JAMBI MEDICAL JOURNAL Jurnal Kedokteran dan Kesehatan ◽

10.22437/jmj.v8i1.9489 ◽

2020 ◽

Vol 8 (1) ◽

pp. 54-59

Author(s):

Hasna Dewi ◽

Fairuz Fairuz

Keyword(s):

Pleural Effusion ◽

Malignant Pleural Effusion ◽

Inflammatory Process ◽

Pleural Cavity ◽

Descriptive Study ◽

Primary Data ◽

Pleural Effusions ◽

Cytological Examination ◽

Male Sex ◽

The Right

ABSTRACT Introduction Pleural effusion is a condition where the fluid either a transudate or an exudate accumulate in pleural cavity. Disease that can cause pleural effusion can be either a malignancy or an inflammatory process. Intratoracal and extratoracal malignancies can cause pleural effusion (malignant pleural effusion / MPE). The aim of this study was to describe the characteristics of patients with pleural effusion and the proportion of malignant pleural effusion in Jambi City. Methods This research is a descriptive study with a retrospective approach, was conducted in 138 sample of pleural effusion patients at two hospital Raden Mattaher and H. Abdul Manap Hospital in 2017-2018. The data was taken from the patient's medical record and primary data in the form of cytological examination results. Results of this study found that most patients with pleural effusion were at the age 40 - 59 years (52.72%), and more men than women (63.77%). The location of the most common effusion was the right hemithorax (52.9%) and the proportion of malignant pleural effusion was only 32.61%. Conclusion Pleural effusion often occurs at the age of 40-59 years with male sex predominant. Most pleural effusions are negative for malignancy, MPE was only 32,61 %. Keywords: characteristics, cytology, malignant pleural effusion (MPE) ABSTRAK Pendahuluan Efusi pleura merupakan keadaan terkumpulnya cairan di dalam rongga pleura, baik itu transudat maupun eksudat. Penyakit yang dapat menyebabkan terjadinya efusi pleura dapat berupa keganasan maupun proses inflamasi. Keganasan intratorakal dan ekstratorakal dapat menimbulkan terjadinya efusi pleura (efusi pleura maligna/EPM). Sampai sekarang belum ada data deskriptif mengenai efusi pleura di kota Jambi. Adapun tujuan penelitian ini mengetahui karakteristik pasien dengan efusi pleura dan proporsi kejadian efusi pleura maligna di Kota Jambi. Metode Penelitian ini adalah penelitian deskritif dengan pendekatan retrospektif. Sampel penelitian merupakan pasien efusi pleura di kota Jambi dari dua RS pemerintah yaitu RSUD Raden Mattaher dan RSUD H. Abdul Manap tahun 2017- 2018 sebanyak 138 sampel. Cara pengambilan sampel dalam penelitan yaitu purposive sampling. Data yang diambil adalah data dari rekam medis pasien dan data primer berupa hasil pemeriksaan sitologi Hasil penelitian ini mendapatkan pasien efusi pleura paling banyak pada proporsi umur 40 – 59 tahun (52,72 %). Jenis kelamin terbanyak adalah laki-laki dengan 88 pasien (63,77%). Lokasi efusi tersering adalah hemithorak dekstra (52,9 %) dan proporsi kejadian efusi pleura maligna hanya 32,61 %. Simpulan Efusi pleura sering terjadi pada usia 40-59 tahun dengan jenis kelamin laki-laki. Sebagian besar efusi pleura adalah negatif maligna, hanya 32,61 % berupa EPM. Kata kunci: efusi pleura maligna (EPM), karakteristik, sitologi

Download Full-text

Drainage of the Pleural Cavity and Chemical Pleurodesis for Malignant Pleural Effusion - Comparison of Bleomycin and Doxycycline

Polish Journal of Surgery ◽

10.2478/v10035-008-0021-6 ◽

2008 ◽

Vol 80 (4) ◽

Author(s):

Grzegorz Kacprzak ◽

Jerzy Kołodziej

Keyword(s):

Pleural Effusion ◽

Malignant Pleural Effusion ◽

Pleural Cavity ◽

Chemical Pleurodesis

Download Full-text

Efferocytosis fuels malignant pleural effusion through TIMP1

Science Advances ◽

10.1126/sciadv.abd6734 ◽

2021 ◽

Vol 7 (33) ◽

pp. eabd6734

Author(s):

Lilan Zhao ◽

Anastasios D. Giannou ◽

Yang Xu ◽

Ahmad Mustafa Shiri ◽

Imke Liebold ◽

...

Keyword(s):

Pleural Effusion ◽

Tyrosine Kinases ◽

Malignant Pleural Effusion ◽

Receptor Tyrosine Kinases ◽

Pleural Cavity ◽

Interleukin 10 ◽

Inflammatory Cascade ◽

Genetic Ablation ◽

Metabolic States ◽

Cell Chemotaxis

Malignant pleural effusion (MPE) results from the capacity of several human cancers to metastasize to the pleural cavity. No effective treatments are currently available, reflecting our insufficient understanding of the basic mechanisms leading to MPE progression. Here, we found that efferocytosis through the receptor tyrosine kinases AXL and MERTK led to the production of interleukin-10 (IL-10) by four distinct pleural cavity macrophage (Mφ) subpopulations characterized by different metabolic states and cell chemotaxis properties. In turn, IL-10 acts on dendritic cells (DCs) inducing the production of tissue inhibitor of metalloproteinases 1 (TIMP1). Genetic ablation of Axl and Mertk in Mφs or IL-10 receptor in DCs or Timp1 substantially reduced MPE progression. Our results delineate an inflammatory cascade—from the clearance of apoptotic cells by Mφs, to production of IL-10, to induction of TIMP1 in DCs—that facilitates MPE progression. This inflammatory cascade offers a series of therapeutic targets for MPE.

Download Full-text

Papillary Thyroid Carcinoma with Malignant Pleural Effusion: Dilemma of Etiology

International Journal of Head and Neck Surgery ◽

10.5005/jp-journals-10001-1023 ◽

2010 ◽

Vol 1 (2) ◽

pp. 117-119 ◽

Cited By ~ 2

Author(s):

Arvind Krishnamurthy ◽

KT Siddappa

Keyword(s):

Thyroid Cancer ◽

Papillary Thyroid Carcinoma ◽

Pleural Effusion ◽

Thyroid Carcinoma ◽

Distant Metastasis ◽

Malignant Pleural Effusion ◽

Standard Treatment ◽

Pleural Cavity ◽

Published Data ◽

Papillary Thyroid

Abstract Papillary carcinomas of thyroid generally have an indolent course with metastatic disease in less than 5% of patients. Common sites of distant metastasis include lung and bone. A presentation with malignant pleural effusion is exceedingly rare with only a handful of cases reported in literature. We present a case and discuss the treatment of a patient presenting of papillary thyroid cancer with a relapse of the disease in the pleural cavity. There are no standard treatment recommendations in this setting in view of paucity of published data from literature.

Download Full-text